Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamou

http://www.prnewswire.com/news-releases/top-line-results-announced-of-pivotal-phase-3-motesanib-trial-in-advanced-non-squamous-non-small-cell-lung-cancer-patients-118901699.html

Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival (OS) (hazard ratio 0.90, 95 percent CI 0.78 – 1.04, p=0.14).

"We are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen.

 

Re: Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squ

And the pipeline grows smaller by 1. Now tell me again. Why do Kevin and Roger get such large bonuses and paychecks?

 

Re: Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squ

KS and the boys are great...sell a dog of a drug to Takeda, let them spend the development money and Amgen still walks aways with millions. Amgen knew it was a dog from the beginning. Not a good way of treating a partner. What other molecules did Amgen sell off that are worthless???

 

Re: Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squ

The only thing I am concerned with is, a nice dividend announcement at the upcoming 4-20-11, 1/4 report, and maybe, even more exciting news at the investment meeting being held the next day.

Prayer meeting will be held the night before and substitutes the regular Bible meeting. The theme will be " money, mo money, mo money"!